{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:25:15Z","timestamp":1788279915135,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Umbilical cord blood transplantation (UCBT) from unrelated donors is one of the successful treatments for acute leukemia in childhood. The most frequent side effect of UCBT is peri-engraftment syndrome (PES), which is directly associated with the greater prevalence of acute and chronic graft-versus-host-disease (aGvHD and cGvHD). In haploidentical stem cell transplantation, posttransplant cyclophosphamide (PTCY) has been demonstrated to be an effective method against GvHD. However, the effects of PTCY as a GvHD prophylactic in UCBT had not been investigated. This study aimed to evaluate the effects of PTCY on the outcomes of UCBT for pediatric acute leukemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study included 52 children with acute leukemia who underwent unrelated single-unit UCBT after myeloablative conditioning regimens. The results from the PTCY and non-PTCY groups were compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The incidence of transplantation-related mortality in non-PTCY and PTCY were 5% and 10% (<jats:italic>p<\/jats:italic>\u2009=\u2009<jats:italic>0.525<\/jats:italic>), respectively. The incidence of relapse in non-PTCY and PTCY were 5% and 23% (<jats:italic>p<\/jats:italic>\u2009=\u2009<jats:italic>0.095<\/jats:italic>), respectively. Second complete remission status (CR2) was an independent risk factor for relapse-free survival (<jats:italic>hazard ratio<\/jats:italic>\u2009=\u20099.782, <jats:italic>p<\/jats:italic>\u2009=\u2009<jats:italic>0.001<\/jats:italic>). The odds ratio for sepsis or bacteremia incidence was significantly greater in the PTCY group (9.524, <jats:italic>p<\/jats:italic>\u2009=\u2009<jats:italic>0.017<\/jats:italic>). PTCY group had increased rates of cytomegalovirus activity and fungal infection. The incidence of PES, aGvHD, cGvHD, and hemorrhagic cystitis in the PTCY group was lower than that in the non-PTCY group, although it was not  significantly different. Additionally, higher doses of PTCY (29\u00a0mg\/kg and 40\u00a0mg\/kg) were associated with lower incidences of aGvHD and severe GvHD (65% and 29%, respectively) than lower doses (93% and 57%, respectively). Engraftment time and graft failure incidence were similar across groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The results support the safety and efficiency of PTCY as part of PES controlling and GvHD prophylaxis in single-unit UCBT for children with acute leukemia. A PTCY dosage of 29\u00a0mg\/kg to 40\u00a0mg\/kg appears to be more effective in GvHD prophylaxis for UCBT patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10309-9","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:03:26Z","timestamp":1668816206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of posttransplant cyclophosphamide on the outcome of patients undergoing unrelated single-unit umbilical cord blood transplantation for pediatric acute leukemia"],"prefix":"10.1186","volume":"22","author":[{"given":"Xin-Yu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian-Dian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia-Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Zhou","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Mei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Pei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Gui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"issue":"1","key":"10309_CR1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/petr.12621","volume":"20","author":"A Iguchi","year":"2016","unstructured":"Iguchi A, Terashita Y, Sugiyama M, et al. Graft-versus-host disease (GVHD) prophylaxis by using methotrexate decreases pre-engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation. Pediatr Transplant. 2016;20(1):114\u20139.","journal-title":"Pediatr Transplant"},{"issue":"1","key":"10309_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/01.TP.0000163289.20406.86","volume":"80","author":"Y Kishi","year":"2005","unstructured":"Kishi Y, Kami M, Miyakoshi S, et al. Early immune reaction after reduced-intensity cord-blood transplantation for adult patients. Transplantation. 2005;80(1):34\u201340.","journal-title":"Transplantation"},{"issue":"4","key":"10309_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.bbmt.2013.01.014","volume":"19","author":"M Park","year":"2013","unstructured":"Park M, Lee SH, Lee YH, et al. Pre-engraftment syndrome after unrelated cord blood transplantation: a predictor of engraftment and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(4):640\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10309_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1600-0609.2011.01709.x","volume":"88","author":"X Wang","year":"2012","unstructured":"Wang X, Liu H, Li L, et al. Pre-engraftment syndrome after unrelated donor umbilical cord blood transplantation in patients with hematologic malignancies. Eur J Haematol. 2012;88(1):39\u201345.","journal-title":"Eur J Haematol"},{"issue":"1","key":"10309_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3346\/jkms.2008.23.1.98","volume":"23","author":"YH Lee","year":"2008","unstructured":"Lee YH, Lim YJ, Kim JY, et al. Pre-engraftment syndrome in hematopoietic stem cell transplantation. J Korean Med Sci. 2008;23(1):98\u2013103.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"10309_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.bbmt.2009.10.022","volume":"16","author":"KJ Patel","year":"2010","unstructured":"Patel KJ, Rice RD, Hawke R, et al. Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(3):435\u201340.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10309_CR7","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.bbmt.2009.07.001","volume":"15","author":"H Frangoul","year":"2009","unstructured":"Frangoul H, Wang L, Harrell FE Jr, et al. Preengraftment syndrome after unrelated cord blood transplant is a strong predictor of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2009;15(11):1485\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10309_CR8","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/s41409-020-0853-1","volume":"55","author":"J Kanda","year":"2020","unstructured":"Kanda J, Umeda K, Kato K, et al. Effect of graft-versus-host disease on outcomes after pediatric single cord blood transplantation. Bone Marrow Transplant. 2020;55(7):1430\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10309_CR9","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.bbmt.2019.02.007","volume":"25","author":"M Isobe","year":"2019","unstructured":"Isobe M, Konuma T, Kato S, et al. Development of Pre-Engraftment Syndrome, but Not Acute Graft-versus-Host Disease, Reduces Relapse Rate of Acute Myelogenous Leukemia after Single Cord Blood Transplantation. Biol Blood Marrow Transplant. 2019;25(6):1187\u201396.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10309_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s12185-019-02598-x","volume":"109","author":"Y Adachi","year":"2019","unstructured":"Adachi Y, Ozeki K, Ukai S, et al. Optimal dosage of methotrexate for GVHD prophylaxis in umbilical cord blood transplantation. Int J Hematol. 2019;109(4):440\u201350.","journal-title":"Int J Hematol"},{"issue":"3","key":"10309_CR11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00277-020-03937-3","volume":"99","author":"S Shiratori","year":"2020","unstructured":"Shiratori S, Ohigashi H, Takahashi S, et al. Reduced dose of MTX for GVHD prophylaxis promotes engraftment and decreases non-relapse mortality in umbilical cord blood transplantation. Ann Hematol. 2020;99(3):591\u20138.","journal-title":"Ann Hematol"},{"issue":"2","key":"10309_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2019.10.022","volume":"26","author":"N Hattori","year":"2020","unstructured":"Hattori N, Saito B, Matsui T, et al. Comparative Study of Tacrolimus and Short-Term Methotrexate: 2-Day versus 3-Day Methotrexate as Graft-versus-Host-Disease Prophylaxis after Umbilical Cord Blood Transplantation in Adults. Biol Blood Marrow Transplant. 2020;26(2):367\u201372.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10309_CR13","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1038\/s41467-021-24412-1","volume":"12","author":"L Jin","year":"2021","unstructured":"Jin L, Sun Z, Liu H, et al. Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients. Nat Commun. 2021;12(1):4137.","journal-title":"Nat Commun"},{"issue":"9577","key":"10309_CR14","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/S0140-6736(07)60915-5","volume":"369","author":"M Eapen","year":"2007","unstructured":"Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369(9577):1947\u201354.","journal-title":"Lancet"},{"issue":"7","key":"10309_CR15","doi-asserted-by":"publisher","first-page":"e13789","DOI":"10.1111\/petr.13789","volume":"24","author":"RCB Tavares","year":"2020","unstructured":"Tavares RCB, Bonfim CS, Seber A, et al. Hematopoietic cell transplantation in pediatric patients with acute leukemias or myelodysplastic syndrome using unrelated adult or umbilical cord blood donors in Brazil. Pediatr Transplant. 2020;24(7):e13789.","journal-title":"Pediatr Transplant"},{"issue":"1","key":"10309_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/sj.bmt.1705539","volume":"39","author":"H Narimatsu","year":"2007","unstructured":"Narimatsu H, Terakura S, Matsuo K, et al. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. Bone Marrow Transplant. 2007;39(1):31\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"10309_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.21037\/sci.2017.05.02","volume":"4","author":"C de Koning","year":"2017","unstructured":"de Koning C, Admiraal R, Nierkens S, et al. Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly. Stem Cell Investig. 2017;4:38.","journal-title":"Stem Cell Investig"},{"issue":"7","key":"10309_CR18","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41409-018-0382-3","volume":"54","author":"J Yang","year":"2019","unstructured":"Yang J, Jiang J, Cai Y, et al. Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study. Bone Marrow Transplant. 2019;54(7):1049\u201357.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10309_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","volume":"56","author":"J Sugita","year":"2021","unstructured":"Sugita J, Kamimura T, Ishikawa T, et al. Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant. 2021;56(3):596\u2013604.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10309_CR20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641\u201350.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10309_CR21","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10309_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389-401 e1.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10309_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12185-014-1510-5","volume":"99","author":"Y Jiang","year":"2014","unstructured":"Jiang Y, Wan LP, Qin YW, et al. Chimerism status is correlated to acute graft-versus-host disease after allogeneic stem cell transplantation. Int J Hematol. 2014;99(3):323\u20138.","journal-title":"Int J Hematol"},{"issue":"6","key":"10309_CR24","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.bbmt.2006.01.009","volume":"12","author":"J Ayello","year":"2006","unstructured":"Ayello J, van de Ven C, Fortino W, et al. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. Biol Blood Marrow Transplant. 2006;12(6):608\u201322.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10309_CR25","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1111\/bcp.14354","volume":"86","author":"H Muranushi","year":"2020","unstructured":"Muranushi H, Kanda J, Arai Y, et al. Drug monitoring for mycophenolic acid in graft-vs-host disease prophylaxis in cord blood transplantation. Br J Clin Pharmacol. 2020;86(12):2464\u201372.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10309_CR26","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/j.bbmt.2016.08.005","volume":"22","author":"N Bejanyan","year":"2016","unstructured":"Bejanyan N, Rogosheske J, DeFor TE, et al. Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2016;22(11):2025\u201330.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10309_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41409-019-0682-2","volume":"55","author":"C Nykolyszyn","year":"2020","unstructured":"Nykolyszyn C, Granata A, Pagliardini T, et al. Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020;55(2):349\u201355.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10309_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1182\/bloodadvances.2019000836","volume":"4","author":"I Politikos","year":"2020","unstructured":"Politikos I, Lavery JA, Hilden P, et al. Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin. Blood Adv. 2020;4(1):191\u2013202.","journal-title":"Blood Adv"},{"issue":"3","key":"10309_CR29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.bbmt.2016.11.014","volume":"23","author":"N Castillo","year":"2017","unstructured":"Castillo N, Garcia-Cadenas I, Barba P, et al. Early and Long-Term Impaired T Lymphocyte Immune Reconstitution after Cord Blood Transplantation with Antithymocyte Globulin. Biol Blood Marrow Transplant. 2017;23(3):491\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"10309_CR30","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.3389\/fimmu.2019.02668","volume":"10","author":"NS Nunes","year":"2019","unstructured":"Nunes NS, Kanakry CG. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding. Front Immunol. 2019;10:2668.","journal-title":"Front Immunol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10309-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10309-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10309-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T15:07:32Z","timestamp":1669129652000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10309-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10309"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10309-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"assertion":[{"value":"5 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutions\u2019 Ethical Committee, and informed consent was obtained from the patients\u2019 parents according to the Declaration of Helsinki in Sun Yat-sen Memorial Hospital of Sun Yat-sen University. The research protocol and informed consent were approved by the ethics committee of Sun Yat-sen Memorial Hospital of Sun Yat-sen University. Consent to participate was obtained from the participants and the parents\/guardians of the children under the age of 18.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1190"}}